1-13 of 13
David J. FitzGerald
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Clinical Trials & Observations Brief Report
Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Steven Coutre, Wyndham H. Wilson, Maryalice Stetler-Stevenson, David J. FitzGerald, Linda Santiago, Guozhi Gao, Mark C. Lanasa, Ira Pastan
Journal: Blood
Blood (2018) 131 (21): 2331–2334.
https://doi.org/10.1182/blood-2017-09-803072
Published: 2018
Includes: Supplemental data
Journal Articles

Targeted diphtheria toxin to treat BPDCN

Clinical Trials & Observations
David J. FitzGerald
Journal: Blood
Blood (2014) 124 (3): 310–312.
https://doi.org/10.1182/blood-2014-06-578633
Published: 2014
Journal Articles

Immunotoxins for leukemia

Clinical Trials & Observations
Alan S. Wayne, David J. FitzGerald, Robert J. Kreitman, Ira Pastan
Journal: Blood
Blood (2014) 123 (16): 2470–2477.
https://doi.org/10.1182/blood-2014-01-492256
Published: 2014
Journal Articles

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Waleed Haso, Daniel W. Lee, Nirali N. Shah, Maryalice Stetler-Stevenson, Constance M. Yuan, Ira H. Pastan, Dimiter S. Dimitrov, Richard A. Morgan, David J. FitzGerald, David M. Barrett, Alan S. Wayne, Crystal L. Mackall, Rimas J. Orentas
Journal: Blood
Blood (2013) 121 (7): 1165–1174.
https://doi.org/10.1182/blood-2012-06-438002
Published: 2013
Includes: Supplemental data
Journal Articles

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

Alan S Wayne, MD, Deepa Bhojwani, MD, Lewis B. Silverman, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PhD, Nirali N Shah, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Manuela Buzoianu, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Ramy Ibrahim, MD, Ira Pastan, MD
Journal: Blood
Blood (2011) 118 (21): 248.
https://doi.org/10.1182/blood.V118.21.248.248
Published: 2011
Journal Articles

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Alan Wayne, MD, Deepa Bhojwani, MD, Kelly Richards, RN, Maryalice Stetler-Stevenson, MD, PHD, Lewis B. Silverman, MD, Sima Jeha, MD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, PhD, Robert J. Kreitman, MD, Robert J. Lechleider, MD, Ira Pastan, MD
Journal: Blood
Blood (2010) 116 (21): 3246.
https://doi.org/10.1182/blood.V116.21.3246.3246
Published: 2010
Journal Articles

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

Robert J. Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H. Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert J. Lechleider, MD, Ira Pastan, MD
Journal: Blood
Blood (2010) 116 (21): 2516.
https://doi.org/10.1182/blood.V116.21.2516.2516
Published: 2010
Journal Articles

Long Term Results of BL22 (CAT-3888) in Multiply Relapsed Hairy Cell Leukemia.

Robert J Kreitman, MD, Wyndham H Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Ira Pastan, MD
Journal: Blood
Blood (2009) 114 (22): 3442.
https://doi.org/10.1182/blood.V114.22.3442.3442
Published: 2009
Journal Articles

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).

Alan S. Wayne, MD, Deepa Bhojwani, MD, Sima Jeha, MD, Maryalice Stetler-Stevenson, MD, PhD, Ching-Hon Pui, MD, Jennifer McDevitt, PharmD, PhD, David J. FitzGerald, Robert J Kreitman, MD, Karen Kaucic, MD, Ira Pastan
Journal: Blood
Blood (2009) 114 (22): 839.
https://doi.org/10.1182/blood.V114.22.839.839
Published: 2009
Journal Articles

Phase I Dose-Escalation Study of CAT-8015 (HA22), A CD22-Specific Targeted Immunotoxin, in Relapsed or Refractory Hairy Cell Leukemia.

Robert J Kreitman, MD, Martin S. Tallman, MD, Steven Coutre, MD, Tadeusz Robak, MD, PhD, Wyndham H Wilson, MD, PhD, Maryalice Stetler-Stevenson, MD, PhD, Pierre Noel, MD, David J. FitzGerald, PhD, Manuela Buzoianu, PhD, Robert Lechleider, MD, Karen Kaucic, MD, Ira Pastan, MD
Journal: Blood
Blood (2009) 114 (22): 888.
https://doi.org/10.1182/blood.V114.22.888.888
Published: 2009
Journal Articles

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity

John E. Weldon, Laiman Xiang, Oleg Chertov, Inger Margulies, Robert J. Kreitman, David J. FitzGerald, Ira Pastan
Journal: Blood
Blood (2009) 113 (16): 3792–3800.
https://doi.org/10.1182/blood-2008-08-173195
Published: 2009
Journal Articles

Interim Phase I Results of Recombinant Immunotoxin HA22 in Patients with Hairy Cell and Chronic Lymphocytic Leukemias

Robert J. Kreitman, MD, Wyndham H. Wilson, Maryalice Stetler-Stevenson, Pierre Noel, David J FitzGerald, Ira Pastan
Journal: Blood
Blood (2008) 112 (11): 3160.
https://doi.org/10.1182/blood.V112.11.3160.3160
Published: 2008
Journal Articles

Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors

Elizabeth Mansfield, Peter Amlot, Ira Pastan, David J. FitzGerald
Journal: Blood
Blood (1997) 90 (5): 2020–2026.
https://doi.org/10.1182/blood.V90.5.2020
Published: 1997